Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ARMCX3
REST API REST API
Homo sapiens
ARMCX3 is differentially expressed in 280 experiments: 122 organism parts: bone marrow, amygdala, ... (120 more);, 169 disease states: normal, control, ... (167 more);, 84 cell types 432 cell lines 41 compound treatments and 72 other conditions.
Synonyms ALEX3
Orthologs ARMCX3 (Bos taurus)   Armcx3 (Mus musculus)   ENSGALG00000008288 (Gallus gallus)   ARMC10 (Danio rerio)   Armcx3 (Rattus norvegicus)   armc10 (Xenopus laevis)   ARMCX3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, membrane, integral to membrane, binding
InterPro Term Armadillo, DUF634
UniProt Accession Q9UH62
Search EB-eye ENSG00000102401
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (40 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
BT-474
2
E-GEOD-5823, E-GEOD-3529
DU145
2
E-GEOD-17482, E-GEOD-20089
GM15510
2
E-GEOD-22639, E-GEOD-19466
MCF-10A
2
E-TABM-420, E-GEOD-14990
MDA468
2
E-MTAB-62, E-MEXP-440
426 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, E-GEOD-13909, ... (43 experiments)

Factor Value U/D Experiments
macrophage
2
E-GEOD-22373, E-GEOD-3982
adult choroid from 76 y.o. donor
1
E-GEOD-18811
single positive thymocyte
1
E-GEOD-1460
n/a
1
E-MTAB-24
activated natural killer cell (supplemented for IL2 for 2 hours)
1
E-TABM-702
testis - leydig cell
1
E-AFMX-5
78 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-16363, E-GEOD-3678, ... (62 experiments)

Factor Value U/D Experiments
control
1
4
E-GEOD-21912, E-GEOD-20602, E-GEOD-16363, E-GEOD-20295, E-GEOD-8121 ... (5 experiments)
multiple myeloma
3
E-MTAB-62, E-GEOD-6691, E-GEOD-2113
dermatomyositis
2
E-GEOD-1551, E-GEOD-5370
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
Lung squamous cell cancer
1
E-MTAB-62
163 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-MEXP-1958, E-MEXP-2590, ... (27 experiments)

Factor Value U/D Experiments
none
3
5
E-TABM-782, E-MEXP-1601, E-GEOD-20719, E-GEOD-995, E-MEXP-2345, ... (8 experiments)
vanadium pentoxide
1
E-GEOD-5339
ponasterone A
1
E-GEOD-3113
MIG control
1
E-GEOD-15811
sapphyrin PCI-2052
1
E-GEOD-6400
tBHP
1
E-MEXP-2345
35 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-2666, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22148, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-TABM-763, E-MEXP-1437, E-GEOD-3494, E-MEXP-149, E-GEOD-17476, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, E-MEXP-1273, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-GEOD-10433, E-GEOD-3606, ... (27 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-7179

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-21750

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-20037 ... (5 experiments)

Replicate
studied in E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307, E-GEOD-1295

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.421 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM